ArticleChest2026
The Impact of the 2023 American Cancer Society Screening Recommendations on Racial, Ethnic, and Sex Disparities in Lung Cancer Screening Eligibility.
Article in Chest, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Maintaining momentum: the history and future of lung cancer disparities in the United States.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundBecause lung cancer risk remains elevated beyond 15 years after smoking cessation, the American Cancer Society (ACS) recommended in 2023 to remove the quit duration criterion from the US Preventive Services Task Force (USPSTF) lung cancer screening guidelines. RESEARCH QUESTION: How do the ACS recommendations impact racial, ethnic, and sex disparities in lung screening eligibility? STUDY DESIGN AND
methodsWe identified adults who currently and formerly smoked from the Black Women's Health Study, Multiethnic Cohort Study, and Southern Community Cohort Study recruited between 1993 and 2009 and followed up through 2019 for lung cancer incidence. Data across cohorts were harmonized. We evaluated the performance of the USPSTF guidelines and ACS recommendations across race, ethnicity, and sex.
resultsAmong 175,259 adults with a smoking history included (42% Black/African American [AA], 25% White American, 15% Japanese American, 12% Hispanic or Latino, 5% Native Hawaiian, and 1% multiracial or other race), 27% (n = 46,702) were eligible for screening according to USPSTF guidelines and 33% (n = 58,373) were eligible according to ACS recommendations. Among those eligible with ACS recommendations but not with USPSTF guidelines (n = 11,671 individuals who formerly smoked), 382 participants (3%) developed lung cancer. ACS recommendations increased eligibility sensitivity, but decreased eligibility specificity among all participants who formerly smoked (USPSTF: sensitivity, 0.34 [95% CI, 0.32-0.35]; specificity, 0.87 [95% CI, 0.87-0.87]; ACS: sensitivity, 0.44 [95% CI, 0.42-0.45]; specificity, 0.77 [95% CI, 0.77-0.77]). These changes differed in magnitude across racial and ethnic groups, resulting in larger eligibility disparities. White American individuals who formerly smoked and developed lung cancer were 3 to 10 percentage points more likely to be eligible for screening with ACS vs USPSTF when compared with their non-White counterparts. The increased disparity was most evident between Black or AA individuals and White American individuals (USPSTF disparity, 7 percentage points; ACS disparity, 12 percentage points) and between Hispanic or Latino and White American individuals (USPSTF disparity, 12 percentage points; ACS disparity, 22 percentage points).
interpretationACS recommendations increased screening eligibility regardless of cancer status, potentially leading to unnecessary screening of people without lung cancer. Despite increased eligibility sensitivity, changes were not uniform across groups, resulting in larger disparities in race and ethnicity and in sex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.